Health care investment firm Patient Square Capital launched a new portfolio company on 2 May called Enavate Sciences, which itself is an investor with $300m that it will use to back therapeutic and enabling technology companies in growth mode. Former life science investment banker and current Enavate CEO James Boylan said now, when many biopharmaceutical firms are running into trouble raising cash, is the right time to launch this new venture.
Boylan most recently served as president and head of investment banking at SVB Leerink, where he led the transformation of the health care investment bank Leerink Swann after its acquisition by SVB Financial in 2019. (Also see "Finance Watch: Biomatics Closes Second VC Fund; SVB Buys Leerink To Expand Life Science Services" - Scrip, 16 November, 2018